OOIR: Observatory of International Research

Papers

(The TQCC of Lancet Respiratory Medicine is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Postoperative CPAP after major abdominal surgery	731
Time to move away from an oxygen-centric model of pulmonary infarction?	554
Why has the incidence of tuberculosis not reduced in London during the COVID-19 pandemic?	546
Concerns regarding a suggested long COVID paradigm – Authors' reply	467
The burden of tuberculosis in Libya	414
European Respiratory Society International Congress 2022	400
Video laryngoscopy is not the nemesis of direct laryngoscopy	373
Major gaps in childhood pneumonia research priorities remain	366
The course of action for effective anti-cytokine treatment in COVID-19	351
Correction to Lancet Respir Med 2024; 12: 129–40	303
Correction to Lancet Respir Med 2019; 7: 745–56	295
Rituximab for connective tissue disease-associated interstitial lung disease	288
Savolitinib in NSCLC: progress in the MET exon 14 journey	269
European Society of Intensive Care Medicine (ESICM) LIVES 35th Annual Congress	268
Chronic obstructive pulmonary disease: 10 years of precision-guided success	262
Broad protection from SARS-CoV-2 variants without antigen matching	254
Concerns about PRISm	239
GOLD report: 2022 update	222
Thoracentesis: an old story and some new sources	219
US Senate committee investigates asthma inhaler prices	206
Eat or heat: fuel poverty and childhood respiratory health	204
Use of fibrinolytics and deoxyribonuclease in adult patients with pleural empyema: a consensus statement	202
Advancing precision medicine for acute respiratory distress syndrome	199
Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials	188
Interstitial lung disease: a decade of progress and hope	188

Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study	187
FLiRTing with danger as SARS-CoV-2 variants evolve	186
Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis	185
Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis	179
Long COVID: systemic inflammation and obesity as therapeutic targets	175
Opioids bring peace to patients with IPF cough	174
One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study	168
Australia bans engineered stone to prevent silicosis	167
Top ten research priorities for breathlessness research: UK James Lind Alliance priority setting partnership	159
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial	158
Genetic associations and lung function in IPF: unexpected answers, persistent questions	157
Improving lifelong respiratory health after preterm birth	153
Cytokine adsorption and ECMO in patients with COVID-19	151
Sarcoidosis and fatigue: there is a useful cognitive treatment? – Authors' reply	151
Claudio Castanos—leader in cystic fibrosis care in Argentina	149
Preoxygenation strategies for intubation of patients who are critically ill: a systematic review and network meta-analysis of randomised trials	143
Priorities for NICE in health and social care	142
US EPA signals renewed regulatory scrutiny of toxic air pollution	141
Solid and semi-solid perspectives in thoracic surgery	140
Nasally delivered SARS-CoV-2 vaccines: future promise and challenges	138
Awake prone positioning in COVID-19: is tummy time ready for prime time?	137
Challenges of modulating the risk of bronchopulmonary dysplasia in clinical trials	136
Overcoming barriers to scaling up tuberculosis preventive treatment for household contacts	136
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial	135
Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis	135
Nintedanib for treating progressive fibrosing interstitial lung diseases	133
Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study	132
Association of SARS-CoV-2 infection and persistence with long COVID	129
Extracorporeal cardiopulmonary resuscitation: not why, but how	128
Misdiagnosis of sarcoidosis	128
Transbronchial cryobiopsy followed by as-needed surgical lung biopsy versus immediate surgical lung biopsy for diagnosing interstitial lung disease (the COLD study): a randomised controlled trial	128
Correction to Lancet Respir Med 2022; 10: 972–84	126
Correction to Lancet Respir Med 2021; 9: 1275–87	126
Health effects of gas fuels: interpreting evidence from a comprehensive meta-analysis	125
Vaccination in the world's top athletes	122
Effectiveness of preventive treatment among different age groups and Mycobacterium tuberculosis infection status: a systematic review and individual-participant data meta-analysis of contact tracing s	119
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, co	119
Correction to Lancet Respir Med 2025; 13: 244–55	119
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis	117
Chronic cough as a disease: implications for practice, research, and health care	116
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CRO	115
Perioperative lung expansion and pulmonary outcomes after open abdominal surgery versus usual care in the USA (PRIME-AIR): a multicentre, randomised, controlled, phase 3 trial	115
Patient with cystic fibrosis not diagnosed until age 23 years now treated with the new triple therapy Trikafta	115
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, doub	114
Endoscopic sinus surgery with medical therapy versus medical therapy for chronic rhinosinusitis with nasal polyps: a multicentre, randomised, controlled trial	113
Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial	113
Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial	111
Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study	111
Trouble with promoting lung cancer screening in never-smokers	107
Venus and Mars: chest wall deformity and thoracic disease	107

NICE guidance on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma	106
COPD: a complex, multifactorial, but preventable disease?	106
Determinants of long-term outcomes in patients with COVID-19 supported with ECMO	106
Underappreciated causes of obstructive lung disease	105
Correction to Lancet Respir Med 2023; 11: 1064–74	102
Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a multicentre, double-blind, randomised, placebo-controlled trial	101
Spirometry in female individuals – Authors' reply	101
Unavailability of varenicline: a global tragedy for the fight against the tobacco epidemic	100
Predicting the future risk of lung cancer: development, and internal and external validation of the CanPredict (lung) model in 19·67 million people and evaluation of model performance against seven ot	100
COVID-19-associated Aspergillus tracheobronchitis: the interplay between viral tropism, host defence, and fungal invasion	100
Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis	100
Prevalence of sleep-disordered breathing in an African general population: The Benin Society and Sleep (BeSAS) study	100
Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials	98
COP27 Climate Change Conference: urgent action needed for Africa and the world	97
Realignment of clinical research after the COVID-19 era	96
Inhaled budesonide for early treatment of COVID-19	96
Liberal or restrictive transfusion for VV ECMO	96
Young person with long COVID after mild disease	96
Developments and priorities in bronchiectasis research	96
Opioid use and sleep apnoea	95
Tackling tuberculosis: what lies beneath the surface?	93
Clean air, climate targets, and respiratory health in Europe	93
Cytokine adsorption during ECMO for COVID-19-related ARDS	93
Choice overload for RSV prevention—how to form your opinion	92
Inhaled budesonide for early treatment of COVID-19 – Authors' reply	89
Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study	89
Individualised, perioperative open-lung ventilation strategy during one-lung ventilation (iPROVE-OLV): a multicentre, randomised, controlled clinical trial	88
Unveiling a hidden phenotype of early tuberculosis	88
Early-life respiratory syncytial virus disease and long-term respiratory health	88
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial	86
Health effects from climate-driven events: lessons learnt	86
SIMPLIFYing cystic fibrosis treatment in a post-modulator era	85
Correction to Lancet Respir Med 2021; published online June 18. https://doi.org/10.1016/S2213-2600(21)00089-8	85
Society of Critical Care Medicine Critical Care Congress 2023	85
The role of small airway dysfunction in asthma control and exacerbations: a longitudinal, observational analysis using data from the ATLANTIS study	85
Time-dependent bias when analysing COVID-19-associated pulmonary aspergillosis – Authors' reply	84
COVID-19—an infectious disease in the top five causes of death in Australia	84
From female warriors in the rainforest to infectious disease specialists: COVID-19 in the Amazon	84
Long-term outcomes of early exposure to repeated general anaesthesia in children with cystic fibrosis (CF-GAIN): a multicentre, open-label, randomised controlled phase 4 trial	83
E-cigarette company tactics in sports advertising	83
Treating acute respiratory illness: the need to be proactive	83
The recent explosion in snortable energy powder consumption	83
Correction to Lancet Respir Med 2022; published online Feb 25. https://doi.org/10.1016/S2213-2600(22)00045-5	82
Wildfires in southern California: concerns for lung health	81
Collateral caring	81
Extracorporeal membrane oxygenation in adults receiving haematopoietic cell transplantation: an international expert statement	79
Managing tuberculosis before the onset of symptoms	79
From lockdown to vaccines: challenges and response in Nepal during the COVID-19 pandemic	79
Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine	77
Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial	75
The effect of inhaled hypertonic saline on lung structure in children aged 3–6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial	75
Core outcome measurement instruments for use in clinical and research settings for adults with post-COVID-19 condition: an international Delphi consensus study	73
Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial	73
High COVID-19 death rates in prisons in England and Wales, and the need for early vaccination	73
Pioneering a paradigm shift in asthma management: remission as a treatment goal	72
Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from tw	72
Lung microbiota predict chronic rejection in healthy lung transplant recipients: a prospective cohort study	72
Home monitoring in interstitial lung diseases	71
Sanjay Ramakrishnan—several lucky turns to arrive at COPD	70
E-cigarettes for smoking reduction: a piece of the public health puzzle	70
Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis	70
Bhutan: small nation, big ideas affecting respiratory health	69
NUTRIREA-3: where to next?	69
Trial emulation with observational data in cystic fibrosis	68
Development of new antibacterial agents: a sense of urgency needed	66
Do B cells rather than eosinophils drive chronic rhinosinusitis with nasal polyps?	65
Moving forward in IPF: lessons learned from clinical trials	64
Cardiac and vascular serious adverse events following tixagevimab–cilgavimab	64
Tackling the global burden of lung disease through prevention and early diagnosis	64
Continuing ECMO with no possible transition to recovery or transplant	62
Continued enteral nutrition until extubation compared with fasting before extubation in patients in the intensive care unit: an open-label, cluster-randomised, parallel-group, non-inferiority trial	61
Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia	61
Waning immunity to SARS-CoV-2: implications for vaccine booster strategies	61
Identification of phenotypes in paediatric patients with acute respiratory distress syndrome: a latent class analysis	59
Rise in group A streptococcal infections in England	59
Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	58
Weaning from mechanical ventilation in intensive care units across 50 countries (WEAN SAFE): a multicentre, prospective, observational cohort study	58
Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies	57
Comparative outcomes of extracorporeal membrane oxygenation for COVID-19 delivered in experienced European centres during successive SARS-CoV-2 variant outbreaks (ECMO-SURGES): an international, multi	57
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicent	57

Common and rare variants and survival in idiopathic pulmonary fibrosis	57
Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled c	56
Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and	56
The importance of post-tuberculosis morbidity in high-income countries	56
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial	55
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised,	54
Postoperative CPAP after major abdominal surgery – Authors' reply	54
US Senate announces planned gun reforms after latest school shooting	53
Lifting the veil on humour and anaesthetics	53
Surviving sepsis with multiple serious complications	52
Determinants of long-term outcomes in patients with COVID-19 supported with ECMO – Authors' reply	52
The upcoming influenza season and protection from vaccines	52
Stubble: the Farmer's Bane	51
Guidelines might help reduce the burden of asthma in African children	51
Flavia Machado—a Latin American leader in sepsis	51
Correction to Lancet Respir Med 2024; 12: 544–55	50
European Lung Cancer Congress 2024	49
Oral corticosteroids for acute preschool wheeze	49
Correction to Lancet Respir Med 2023; published online Feb 3. https://doi.org/10.1016/S2213-2600(22)00491-X	49
Community-acquired pneumonia: the best candidates for clarithromycin	47
Fighting sepsis: still a long way to go	47
Surviving COVID-19: a familiar road to recovery?	46
Changes in rates of prescriptions for inhaled corticosteroids during the COVID-19 pandemic	46
Neomi Shah—cracking the conundrum of sleep disorders	46
Reflections 5 years on from the approval of ETI therapy	46
Patient in her 70s with COPD and asthma improving significantly since using monoclonal antibody dupilumab	46
ECMO: more than just a bridge over troubled waters?	45
Misconceptions regarding symptoms of sarcoidosis	45
Persistence of SARS-CoV-2 RNA in lung tissue after mild COVID-19	44
Effect of non-invasive ventilation after extubation in critically ill patients with obesity in France: a multicentre, unblinded, pragmatic randomised clinical trial	44
Chronic respiratory disease in Indigenous peoples: a framework to address inequity and strengthen respiratory health and health care globally	44
Chronic thromboembolic pulmonary hypertension: realising the potential of multimodal management	44
International guideline recommendations and eligibility criteria for home oxygen therapy	44
Use of lung-cancer trends for global and public health priorities	44
Development of an asthma health-care burden score as a measure of severity and predictor of remission in SARP III and U-BIOPRED: results from two major longitudinal asthma cohorts	43
Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study	42
The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study	42
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial	42
Perioperative lung expansion and pulmonary outcomes after abdominal surgery	41
Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study	40
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial	40
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled,	40
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomi	40
Vascular mechanisms and manifestations of COVID-19	39
US EPA strengthens PM2·5 air pollution limits	39
It is time to include real-world effectiveness data on medicinal product labels	39
High-dose rifampicin to treat tuberculosis infection: potential and pitfalls	38
Remdesivir saves lives. Were 3 years needed to learn that?	38
Home-based monitoring in chronic respiratory diseases: in search of Panacea	38
IL-6 blockade for COVID-19: a global scientific call to arms	38
How Glasgow's 1957 tuberculosis screening programme could help countries today	38
A leap forward in assessing host-directed therapies for tuberculosis	37
Lockdown as the mother of invention: disruptive technology in a disrupted time	37
Convalescent plasma in outpatients with COVID-19	37
Discussions on VT4COVID	37
Tuberculosis prevalence: beyond the tip of the iceberg	36
Time to escalate quality assurance in small-cell lung cancer radiotherapy trials – Authors' reply	36
Correction Lancet Respir Med 2022; 10: 937–48	36
Correction to Lancet Respir Med 2025; 13: 318–26	35
Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial	35
Understanding clinical and biological heterogeneity to advance precision medicine in paediatric acute respiratory distress syndrome	35
Concerns regarding a suggested long COVID paradigm	35
Could a good night's sleep improve COVID-19 vaccine efficacy?	35
The passage of Ireland's Human Tissue Act: challenges, consequences, and cross-border cooperation	35
Outcome predictors and patient progress following delivery in pregnant and postpartum patients with severe COVID-19 pneumonitis in intensive care units in Israel (OB-COVICU): a nationwide cohort study	34
Air pollution, climate change, and lung health in Europe	34
Knowledge gaps in fibrotic interstitial lung disease in pan-Asian populations: data not missing at random?	34
SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys	34
Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-	34
Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis	33
C-reactive protein-guided treatment in pneumonia: charting a personalised approach – Authors’ reply	33
Time to move away from an oxygen-centric model of pulmonary infarction? – Authors' reply	33
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomise	33
Online mindfulness-based cognitive therapy for fatigue in patients with sarcoidosis (TIRED): a randomised controlled trial	33
What is next for BCG revaccination to prevent tuberculosis?	33
The 2021 USPSTF lung cancer screening guidelines: a new frontier	33
Addressing the post-acute sequelae of SARS-CoV-2 infection: a multidisciplinary model of care	33
Philip Morris International purchases Vectura	33
Addressing the origins and health effects of small lungs	32
Concerning the use of aminoglycosides in ventilator-associated pneumonia – Authors' reply	32
Sedative medications: an avoidable cause of asthma and COPD exacerbations?	32
Chronic obstructive pulmonary disease: new therapies and old needs	31
Idiopathic inflammatory myopathies related lung disease in adults	31
The future of paediatric acute respiratory distress syndrome	30
Volcanic eruption in Tonga and effects on respiratory health	30
Trouble with promoting lung cancer screening in never-smokers – Authors' reply	30
Confounding undermines inferences of preventive therapy effectiveness among subgroups of tuberculosis contacts	29
Baseline characteristics of patients in the Chinese Bronchiectasis Registry (BE-China): a multicentre prospective cohort study	29
The Wuhan lockdown	29
Pirfenidone in patients with non-IPF progressive fibrotic interstitial lung diseases: expert guidance is urgently needed	28
Integrating new therapies for systemic sclerosis-associated lung fibrosis in clinical practice	28
Early postnatal high-dose fat-soluble enteral vitamin A supplementation for moderate or severe bronchopulmonary dysplasia or death in extremely low birthweight infants (NeoVitaA): a multicentre, rando	28
Tuberculosis, conflict, and displacement	27
Living with spinal muscular atrophy while working in critical care	26
Supporting families with tuberculosis during COVID-19 in Khayelithsa, South Africa	26